SPCC16A11.15c Antibody

What is SPCC16A11.15c protein and why is it studied?

SPCC16A11.15c is a protein expressed in Schizosaccharomyces pombe (strain 972 / ATCC 24843), commonly known as fission yeast. The protein is cataloged in the UniProt database with the accession number Q9USM2 . Studying this protein contributes to our understanding of S. pombe biology, which serves as an important model organism for investigating eukaryotic cellular processes including cell division, DNA replication, and chromosome dynamics. Research on S. pombe proteins like SPCC16A11.15c allows scientists to draw parallels to homologous human cellular mechanisms, potentially providing insights into disease processes and therapeutic targets. When designing experiments involving this protein, researchers typically employ genetic approaches to manipulate its expression and antibody-based methods to detect and quantify it in various experimental contexts .

What are the recommended applications for SPCC16A11.15c antibody?

The SPCC16A11.15c antibody has been validated for specific laboratory applications based on its binding characteristics and specificity profile. According to available data, this antibody is successfully employed in:

• Enzyme-Linked Immunosorbent Assay (ELISA) - For quantitative detection of the target protein in solution

• Western Blot (WB) - For identification of the protein in cell lysates and tissue homogenates

While these represent the tested applications, researchers should be aware that potential applications might extend to immunofluorescence (IF) or immunoprecipitation (IP) following appropriate validation experiments. Each application requires specific optimization parameters, including antibody dilution, incubation conditions, and buffer compositions. When planning experiments, researchers should conduct preliminary titration studies to determine optimal working concentrations for their specific experimental system .

How should SPCC16A11.15c antibody be properly stored and handled?

Proper storage and handling of SPCC16A11.15c antibody is critical for maintaining its functionality and extending its usable lifespan. The recommended storage conditions include:

When working with the antibody, allow it to equilibrate to room temperature before opening the vial to prevent condensation and potential contamination. For long-term experimental planning, note that the antibody is supplied in liquid form and has been affinity-purified to enhance specificity . Documentation of storage conditions, date of receipt, and freeze-thaw cycles in laboratory notebooks is recommended for troubleshooting variability in experimental results.

What validation methods should be employed before using SPCC16A11.15c antibody?

Before incorporating SPCC16A11.15c antibody into critical experiments, researchers should verify its specificity and sensitivity using established validation approaches. Based on the "five pillars" of antibody validation framework, the following methods are recommended:

• Genetic strategies: Testing the antibody in cells where SPCC16A11.15c has been knocked out or knocked down to confirm specificity. This represents the gold standard approach as it directly tests for non-specific binding .

• Orthogonal strategies: Comparing antibody-dependent detection methods with antibody-independent techniques (such as mass spectrometry or RNA-seq) to confirm detection of the same target .

• Independent antibody strategies: Utilizing multiple antibodies targeting different epitopes of SPCC16A11.15c to validate observations. This requires knowledge of each antibody's binding region on the target protein .

• Recombinant expression: Overexpressing SPCC16A11.15c in a controlled system to confirm antibody detection with increasing signal corresponding to increased expression levels.

• Immunocapture with mass spectrometry: Capturing proteins with the antibody and analyzing by mass spectrometry to confirm the identity of bound proteins.

These validation approaches should be selected based on the intended application and available resources. Each method has strengths and limitations that must be considered in the experimental design .

What controls should be included when using SPCC16A11.15c antibody in experiments?

Appropriate experimental controls are essential for reliable interpretation of results when working with SPCC16A11.15c antibody. The following controls should be integrated into experimental design:

Including these controls allows researchers to distinguish specific from non-specific signals and provides a framework for troubleshooting unexpected results. For quantitative applications, standard curves using recombinant SPCC16A11.15c at known concentrations should be considered to establish the relationship between signal intensity and protein abundance .

How does the specificity of SPCC16A11.15c antibody vary across different experimental techniques?

The specificity of SPCC16A11.15c antibody can vary significantly across different experimental techniques due to variations in sample preparation, protein conformation, and detection methods. Based on antibody characterization principles, the following technique-specific considerations should be addressed:

Western Blot (WB): In denaturing conditions, the antibody recognizes linear epitopes of SPCC16A11.15c. Specificity in WB can be evaluated by observing a single band at the expected molecular weight. If multiple bands appear, additional validation is required to determine if they represent specific splice variants, post-translational modifications, or non-specific binding .

ELISA: In solution-phase detection, the antibody interacts with native or partially denatured protein. Higher specificity may be achieved when using sandwich ELISA with two antibodies recognizing different epitopes of SPCC16A11.15c. When developing ELISA protocols, optimize antibody concentration and blocking conditions to minimize background signal .

Immunoprecipitation: If adapting this antibody for IP applications, native protein conformation becomes crucial. The affinity-purified nature of this antibody makes it potentially suitable for IP, but pilot experiments should assess recovery efficiency and non-specific binding to beads or other cellular components .

Researchers should validate the antibody independently for each experimental technique rather than assuming uniform performance across applications. Cross-technique validation strengthens confidence in experimental results and helps identify technique-specific limitations .

What approaches can optimize Western blot protocols specifically for SPCC16A11.15c antibody?

Optimizing Western blot protocols for SPCC16A11.15c antibody requires systematic adjustment of multiple parameters to achieve maximum sensitivity and specificity. The following optimization strategy is recommended:

• Sample preparation optimization:

  • Include protease inhibitors to prevent target degradation

  • Test different lysis buffers (RIPA, NP-40, etc.) to maximize protein extraction

  • Optimize protein loading (typically 20-50 μg total protein)

• Electrophoresis and transfer parameters:

  • Select appropriate gel percentage based on SPCC16A11.15c molecular weight

  • Optimize transfer conditions (time, voltage, buffer composition)

  • Consider wet transfer for larger proteins or semi-dry for smaller proteins

• Antibody incubation optimization:

  • Test a dilution series (1:500, 1:1000, 1:2000, etc.) to determine optimal concentration

  • Compare overnight incubation at 4°C versus shorter incubations at room temperature

  • Evaluate different blocking agents (BSA vs. non-fat milk) for signal-to-noise ratio

• Detection system selection:

  • Compare chemiluminescence, fluorescence, and colorimetric detection methods

  • For quantitative analysis, consider fluorescence-based systems with broader dynamic range

Systematic optimization should isolate individual variables while keeping others constant, allowing precise determination of optimal conditions. Document all optimization experiments thoroughly for reproducibility and future reference .

What are the known cross-reactivity issues with SPCC16A11.15c antibody and how can they be mitigated?

While specific cross-reactivity data for SPCC16A11.15c antibody is limited in the available literature, polyclonal antibodies generally have higher potential for cross-reactivity compared to monoclonal antibodies due to their recognition of multiple epitopes. Based on general antibody characterization principles, the following approaches can address potential cross-reactivity:

• Species cross-reactivity assessment:

  • This antibody is raised against Schizosaccharomyces pombe protein and tested for reactivity with this species

  • Cross-reactivity with proteins from other species depends on sequence conservation

  • When using in non-tested species, validation experiments are essential

• Epitope analysis:

  • Perform in silico analysis of protein sequence similarity between SPCC16A11.15c and other proteins

  • Identify regions of high homology that might contribute to cross-reactivity

• Cross-reactivity mitigation strategies:

  • Pre-adsorption with proteins from species or tissues where cross-reactivity occurs

  • Increasing wash stringency (higher salt concentration, detergent percentage)

  • Optimization of antibody concentration to favor high-affinity specific binding

  • Use of knockout/knockdown controls to distinguish specific from non-specific signals

• Alternative detection strategies:

  • Employing the "independent antibody strategy" with antibodies targeting different epitopes

  • Confirming key findings with orthogonal, antibody-independent methods

When cross-reactivity is observed, document the pattern and molecular weights of cross-reactive species to develop targeted mitigation strategies. Incorporation of appropriate negative controls allows confident discrimination between specific and non-specific signals .

How can binding kinetics and affinity of SPCC16A11.15c antibody be quantitatively assessed?

Quantitative assessment of SPCC16A11.15c antibody binding kinetics and affinity provides valuable insights for experimental design and data interpretation. Several methodologies can be employed for this characterization:

• Surface Plasmon Resonance (SPR):

  • Immobilize recombinant SPCC16A11.15c protein on a sensor chip

  • Flow antibody at varying concentrations across the chip

  • Measure association (ka) and dissociation (kd) rates

  • Calculate equilibrium dissociation constant (KD = kd/ka)

  • Advantages: Real-time measurement, no labeling required

• Bio-Layer Interferometry (BLI):

  • Similar principles to SPR but using optical interference patterns

  • Suitable for crude samples with less stringent purification requirements

  • Provides ka, kd, and KD values

• Isothermal Titration Calorimetry (ITC):

  • Measures heat released or absorbed during binding

  • Provides thermodynamic parameters (ΔH, ΔS) in addition to KD

  • Requires larger sample volumes but gives comprehensive binding profile

• Enzyme-Linked Immunosorbent Assay (ELISA):

  • Simpler approach using serial dilutions of antibody

  • Plot binding curve and calculate apparent KD

  • Less precise than biophysical methods but more accessible

Understanding the binding kinetics helps interpret experimental results, especially when comparing different lots of antibody or troubleshooting experimental variability. For critical applications, comparing the affinity of different anti-SPCC16A11.15c antibodies can guide selection of the most appropriate reagent .

What troubleshooting approaches are recommended for non-specific binding issues with SPCC16A11.15c antibody?

Non-specific binding can compromise experimental results when working with SPCC16A11.15c antibody. A systematic troubleshooting approach based on antibody characterization principles includes:

• Identifying the source of non-specific binding:

  • Background pattern analysis (diffuse vs. discrete bands/signals)

  • Molecular weight assessment of non-specific signals

  • Comparison with negative controls (knockout/knockdown samples)

• Optimizing blocking conditions:

  • Test different blocking agents (BSA, non-fat milk, commercial blockers)

  • Increase blocking duration (1-3 hours at room temperature)

  • Consider adding protein from non-related species (e.g., fish gelatin)

• Adjusting antibody parameters:

  • Titrate primary antibody concentration (typically testing 2-5 dilutions)

  • Reduce incubation temperature (4°C instead of room temperature)

  • Add low concentration of detergent (0.05-0.1% Tween-20) to antibody diluent

• Increasing wash stringency:

  • Extend wash durations (5-15 minutes per wash)

  • Increase number of washes (4-6 instead of standard 3)

  • Adjust salt concentration in wash buffer (150-500 mM NaCl)

  • Test different detergents (Tween-20, Triton X-100) at varying concentrations

• Sample-specific approaches:

  • Pre-adsorb antibody with proteins from species or tissues showing cross-reactivity

  • Pre-clear lysates with Protein A/G beads to remove components binding non-specifically

  • Filter samples to remove aggregates that might trap antibodies

For persistent non-specific binding issues, consider implementing more rigorous validation approaches such as the genetic strategy (using knockout/knockdown systems) or orthogonal strategy (comparing with antibody-independent methods) as described in the "five pillars" framework for antibody validation .

How should experiments be designed to compare results from SPCC16A11.15c antibody with other detection methods?

• Sample preparation consistency:

  • Use identical samples for all detection methods

  • Process samples simultaneously to minimize variability

  • Maintain careful documentation of all processing steps

• Method selection and integration:

  • Antibody-dependent methods: Western blot, ELISA, immunofluorescence

  • Antibody-independent methods: RT-qPCR (mRNA levels), mass spectrometry (protein levels)

  • Functional assays relevant to SPCC16A11.15c's biological role

• Quantitative comparison framework:

  • Establish normalization strategy across methods

  • Use appropriate statistical tests to evaluate correlation between methods

  • Consider Bland-Altman analysis to assess agreement between methods

• Interpretation guidelines:

  • Perfect correlation between methods is rarely achieved due to biological and technical factors

  • Discrepancies may reveal biologically relevant insights (e.g., post-transcriptional regulation)

  • Consistent trends across methods generally provide stronger evidence than absolute values

What statistical approaches are recommended for analyzing quantitative data from SPCC16A11.15c antibody experiments?

Transparency in reporting statistical methods is critical for reproducibility. Documentation should include software packages used, specific tests applied, and any data transformations performed prior to analysis .

How can SPCC16A11.15c antibody be incorporated into multi-parameter experimental workflows?

Integrating SPCC16A11.15c antibody into multi-parameter experimental workflows enhances the depth and context of research findings. The following approaches facilitate this integration:

• Multiplexed immunodetection:

  • Combine SPCC16A11.15c antibody with antibodies against other proteins of interest

  • For Western blots: Use different species antibodies with species-specific secondary antibodies

  • For immunofluorescence: Select primary antibodies from different species and use spectrally distinct fluorophores

• Integration with omics techniques:

  • Correlate SPCC16A11.15c protein levels with transcriptomics data

  • Combine with phosphoproteomics to assess functional state

  • Integrate with interactome studies to identify protein-protein interactions

• Temporal experimental designs:

  • Time-course studies to track dynamic changes in SPCC16A11.15c

  • Pulse-chase experiments to study protein stability and turnover

  • Live-cell imaging with fluorescently tagged antibody fragments

• Spatial analysis integration:

  • Combine with subcellular fractionation to assess localization

  • Integrate with proximity labeling methods (BioID, APEX) to map local interactome

  • Correlate with high-resolution microscopy for precise spatial information

When designing multi-parameter experiments, consider potential interference between detection methods and validate each parameter independently before combination. Data integration across multiple parameters often requires specialized bioinformatic approaches to identify meaningful patterns and correlations .

What critical information should be reported in publications using SPCC16A11.15c antibody?

Comprehensive reporting of antibody-related information is essential for experimental reproducibility. When publishing research using SPCC16A11.15c antibody, the following details should be included:

• Antibody identification information:

  • Commercial source and catalog number (e.g., CSB-PA892391XA01SXV from Cusabio)

  • Clone number (for monoclonal) or lot number (for polyclonal)

  • RRID (Research Resource Identifier) if available

  • Species raised in (rabbit)

  • Clonality (polyclonal)

• Validation information:

  • Validation methods employed (e.g., genetic strategy, orthogonal strategy)

  • Results of validation experiments

  • Known limitations or cross-reactivities

  • Reference to previous validation studies if available

• Experimental conditions:

  • Antibody concentration or dilution used

  • Incubation conditions (time, temperature, buffer)

  • Detection method details (secondary antibody, visualization system)

  • Complete protocols or references to detailed methods

• Controls employed:

  • Positive and negative controls

  • Technical validation controls

  • Quantification controls (standard curves, loading controls)

This level of reporting aligns with the "Minimum Information About a Protein Affinity Reagent" (MIAPAR) guidelines and the broader "Minimum Information for Biological and Biomedical Investigations" (MIBBI) framework. Journal editors and reviewers increasingly require this information to ensure experimental reproducibility .

How can inter-laboratory reproducibility be maximized when using SPCC16A11.15c antibody?

Maximizing inter-laboratory reproducibility requires standardization of critical parameters and detailed documentation. The following strategies enhance reproducibility when working with SPCC16A11.15c antibody:

• Antibody source standardization:

  • Use the same catalog number and, ideally, lot number across laboratories

  • Establish reference stocks that can be shared between collaborating labs

  • Consider creating a laboratory "antibody passport" documenting validation results

• Protocol standardization:

  • Develop and share detailed standard operating procedures (SOPs)

  • Specify critical reagents, equipment, and environmental conditions

  • Identify protocol steps sensitive to variation and provide troubleshooting guidance

• Quality control implementation:

  • Include standard positive and negative controls in all experiments

  • Establish acceptance criteria for control results

  • Consider including reference samples that can be shared between laboratories

• Data sharing and analysis standardization:

  • Use common data formats and analysis pipelines

  • Share raw data along with processed results

  • Document all analysis steps, including software versions and parameters

How should contradictory results from different batches of SPCC16A11.15c antibody be interpreted and addressed?

• Systematic investigation of batch differences:

  • Re-validate each antibody batch using the same validation methods

  • Compare validation results between batches quantitatively

  • Determine if differences are in sensitivity, specificity, or both

• Technical troubleshooting:

  • Test identical samples with different antibody batches in parallel

  • Systematically adjust experimental conditions to determine if optimizing protocols can resolve discrepancies

  • Evaluate if batch-specific optimal conditions can be established

• Independent verification approaches:

  • Implement orthogonal, antibody-independent methods to verify findings

  • Use the "independent antibody strategy" with antibodies targeting different epitopes

  • Consider advanced approaches like epitope mapping to understand binding differences

• Reporting and interpretation framework:

  • Document all batch information and observed differences

  • When publishing, clearly indicate which batch was used for which experiments

  • Discuss potential implications of batch differences for data interpretation

When encountering significant batch-to-batch variability, contact the manufacturer to report findings and inquire about known production changes. For critical experiments, consider purchasing larger quantities of a single batch to ensure consistency throughout a project .

What emerging technologies might enhance the utility of SPCC16A11.15c antibody in research?

Emerging technologies are expanding the capabilities and applications of research antibodies like SPCC16A11.15c antibody. These innovations offer new opportunities for detection, quantification, and functional analysis:

• Advanced imaging technologies:

  • Super-resolution microscopy for nanoscale localization

  • Expansion microscopy for physical magnification of specimens

  • Light-sheet microscopy for rapid 3D imaging with reduced photobleaching

  • These approaches could reveal previously undetectable spatial details of SPCC16A11.15c distribution and interactions

• Single-cell protein analysis:

  • Mass cytometry (CyTOF) for multiplexed protein detection

  • Microfluidic antibody capture for single-cell proteomics

  • Single-cell Western blotting technologies

  • These methods could uncover cell-to-cell variability in SPCC16A11.15c expression and modification

• Proximity-based interaction analysis:

  • Proximity ligation assay (PLA) to detect protein-protein interactions in situ

  • Split-protein complementation assays for live monitoring of interactions

  • These techniques could map the interactome of SPCC16A11.15c with spatial and temporal resolution

• Antibody engineering advancements:

  • Generation of recombinant antibody fragments with enhanced tissue penetration

  • Site-specific conjugation chemistry for precise labeling

  • Nanobodies and single-domain antibodies with reduced size

  • These developments could improve specificity and versatility of SPCC16A11.15c detection

Researchers should monitor literature for validation of these technologies with antibodies similar to SPCC16A11.15c and consider pilot studies to assess their applicability to specific research questions. Each new technology requires appropriate controls and validation procedures to ensure reliable results .

How might genetic engineering approaches complement or enhance SPCC16A11.15c antibody-based studies?

Genetic engineering approaches provide powerful complementary methods to antibody-based detection of SPCC16A11.15c, offering independent validation and additional functional insights:

• CRISPR/Cas9 genome editing:

  • Generate knockout strains as negative controls for antibody validation

  • Create knockin strains with epitope tags for alternative detection

  • Introduce point mutations to study structure-function relationships

  • These approaches provide definitive controls for antibody specificity and enable functional studies

• Endogenous tagging strategies:

  • Fluorescent protein fusion for live imaging

  • Proximity-dependent labeling tags (BioID, APEX) for interactome mapping

  • Degron tags for controlled protein degradation

  • These methods allow visualization and manipulation of SPCC16A11.15c in its native context

• Inducible expression systems:

  • Tetracycline-regulated or other inducible promoters

  • Auxin-inducible degron systems for rapid protein depletion

  • Optogenetic control of protein expression or activity

  • These systems enable temporal control of SPCC16A11.15c levels for dynamic studies

• Reporter strain development:

  • Luciferase or fluorescent reporters linked to SPCC16A11.15c promoter

  • Split reporters for detecting protein-protein interactions

  • These constructs provide real-time readouts of gene expression or protein interactions

Combining genetic engineering with antibody-based detection provides multiple independent lines of evidence and enables comprehensive characterization of SPCC16A11.15c function. This integrated approach aligns with the "orthogonal strategy" and "genetic strategy" pillars of antibody validation .

How can computational approaches improve SPCC16A11.15c antibody specificity prediction and epitope mapping?

Computational methods offer valuable tools for predicting antibody specificity and mapping epitopes, which can enhance experimental design and data interpretation for SPCC16A11.15c antibody:

• In silico epitope prediction:

  • B-cell epitope prediction algorithms to identify likely binding regions

  • Structural modeling to predict surface-exposed regions of SPCC16A11.15c

  • Sequence conservation analysis to identify unique regions for specific targeting

  • These approaches can guide selection of antibodies targeting non-conserved regions to minimize cross-reactivity

• Cross-reactivity prediction:

  • BLAST or other sequence similarity searches to identify potential cross-reactive proteins

  • Epitope mapping aligned with proteome-wide searches for similar motifs

  • Structural modeling of antibody-antigen interactions

  • These methods identify potential sources of non-specific binding before experimental testing

• Machine learning applications:

  • Prediction of antibody performance based on sequence and structural features

  • Classification of potential cross-reactive epitopes

  • Optimization of experimental conditions based on antibody-antigen properties

  • These emerging approaches leverage growing databases of antibody characteristics

• Integrative data analysis:

  • Combining antibody binding data with protein interaction networks

  • Correlating epitope accessibility with protein functional states

  • Interpreting unexpected binding patterns in the context of protein modifications

  • These methods connect antibody binding patterns with biological function